Popular in Psychology

Most Cited

The adapted mind

Dalhousie University Jerome Barkow

Psychology

Consumers’ pursuit of material and experiential purchases

Cornell University Tom Gilovich

Experimental Psychology

Time to investigate human visual shape perception

University of Montreal Martin Arguin

Most Cited

James S. Jackson and the program for research on Black Americans

Harvard University David R. Williams

Psychology

Violence and Mental Illness: Rethinking Risk Factors and Enhancing Public Safety

Duke University Eric Elbogen

Cognitive Psychology

Cognitive remediation – where are we now and what should we do next?

King's College London Til Wykes

Cognitive Psychology

Harnessing Plasticity in the Atypical Developing Brain using Neurostimulation

University of Surrey Roi Cohen Kadosh

Haemoglobin Concentration Improves Prediction of Cognitive Outcomes in Patients with Sickle Cell Anemia

View more insights in Social Sciences - Psychology - Behavioural Neuroscience - Experimental Psychology

View more figures from University of Manchester

View the page of Anna Hood

Read the Study

Next in Behavioural Neuroscience

Metaphorical language processing and amygdala activation in non-native and native speakers

Francesca Citron | Lancaster University

Insensitivity to future repercussions after prefrontal cortex damage

Antoine Bechara | University of Southern California

Sickle cell anemia (SCA) is associated with cognitive challenges that often worsen as children age. Anna Hood discusses the first study of pediatric patients with SCA to examine the extent to which indices of Haemoglobin Concentration control may provide additional prognostic information.

Image courtesy of interviewee. July 10, 2024

Log-in or Sign-up to Faculti
Currently viewing this subject insight as a guest. You have insight(s) remaining for this month. Login to view 8000+ figures on the platform.

Generating Workspace...

Export as PDF

This video discusses sickle cell disease (SCD), the most common inherited disorder globally, which is rapidly growing in the UK. SCD affects hemoglobin in red blood cells, leading to their sickle shape, which impairs oxygen transport throughout the body, particularly affecting the brain. This video can result in cognitive challenges, especially in processing speed and executive functions, crucial for daily life and education.

The author highlights a study aimed at examining the relationship between hemoglobin levels and cognitive outcomes over time, utilizing longitudinal data collected from children with SCD in the UK from 2005 to 2014. Results indicated that higher mean hemoglobin levels were significantly associated with better processing speed but not necessarily with working memory or the presence of silent infarctions in the brain.

This video also emphasizes recent advancements in treatments for SCD, including emerging drugs that specifically target hemoglobin improvement, which could lead to better cognitive outcomes. The author calls for more longitudinal studies and the integration of cognitive assessments in clinical trials for SCD treatments to provide a more comprehensive understanding of the disorder's impact on patients' cognitive functions.

Language:

Export as PDF

X-TIMESTAMP-MAP:LOCAL=00:00:00.000,MPEGTS=900000

00:00.000 --> 00:02.405
Sickle cell or sickle cell, disease

00:02.405 --> 00:04.005
or anemia, as it's often called,

00:04.625 --> 00:07.765
is actually the most common inherited disorder in the world

00:07.905 --> 00:09.445
and is actually the fastest growing

00:09.445 --> 00:11.165
inherited disorder here in the uk.

00:11.745 --> 00:14.565
Um, and what it affects is the hemoglobin

00:14.585 --> 00:15.765
in our red blood cells.

00:16.105 --> 00:19.725
And so hemoglobin is what carries oxygen around the body.

00:20.225 --> 00:23.325
Um, and in, sickle cell, that,

00:23.325 --> 00:25.045
process sort of breaks down.

00:25.505 --> 00:29.405
Um, and, that process breaking down means the,

00:29.505 --> 00:31.205
red blood cells take on the shape

00:31.225 --> 00:33.085
of a sickle giving it its name,

00:33.625 --> 00:37.685
and it means that those cells are poor oxygen carriers.

00:37.785 --> 00:40.005
So they, you know, you've gotta get oxygen to all

00:40.005 --> 00:42.725
of our organs around the body, including the brain,

00:42.725 --> 00:45.205
which is our biggest sucker, essentially,

00:45.205 --> 00:46.365
really needs oxygen.

00:46.785 --> 00:50.045
Um, and so those sickle cells don't carry oxygen very well.

00:50.145 --> 00:51.925
And unfortunately they're quite sticky

00:52.025 --> 00:54.565
and they get caught in the red blood cells,

00:55.025 --> 00:56.725
and, in our vessels

00:56.985 --> 00:59.365
and stop the healthy blood cells getting through.

00:59.905 --> 01:03.445
And so, one of the challenges that can face

01:03.445 --> 01:05.485
because of having lack of oxygen is

01:05.505 --> 01:06.765
to the brain, as I mentioned.

01:07.025 --> 01:09.085
And so not having enough oxygen to the brain,

01:09.185 --> 01:10.845
as you can imagine, can cause sort

01:10.845 --> 01:12.085
of this cascade of problems.

01:12.385 --> 01:15.045
But one of the things I'm particularly interested in is how

01:15.045 --> 01:16.445
that affects cognition.

01:16.585 --> 01:19.645
So the thinking abilities, what we need to be able to do at,

01:19.785 --> 01:22.565
at school to do well, for the chil,

01:22.565 --> 01:23.805
young children and young people.

01:23.985 --> 01:26.125
And then obviously into adulthood, being able

01:26.125 --> 01:27.445
to manage our day-to-day lives.

01:27.945 --> 01:30.885
And so not having, enough hemoglobin that's going

01:30.885 --> 01:32.085
to the brain means

01:32.085 --> 01:35.005
that these cognitive challenges occur sort of across

01:35.515 --> 01:37.285
many different types of cognition,

01:37.545 --> 01:40.405
but particularly around, processing speed.

01:40.465 --> 01:44.845
So being able to take in information, understand what it is,

01:44.865 --> 01:45.965
and process it quickly.

01:46.585 --> 01:49.285
And something called executive functions, which are sort

01:49.285 --> 01:50.725
of these higher level,

01:50.835 --> 01:53.165
cognition challenges and thinking abilities.

01:53.585 --> 01:56.045
So being able to do multiple things at once

01:56.305 --> 01:59.165
or flex, be flexible from moving one to,

01:59.165 --> 02:00.205
from one thing to the other.

02:00.505 --> 02:03.125
And so this study was, because, myself

02:03.125 --> 02:05.325
and my colleagues have been interested in this area in

02:05.325 --> 02:09.525
thinking about how can we, improve hemoglobin,

02:09.905 --> 02:12.205
and so what's the process, that's happening?

02:12.205 --> 02:14.725
What are the underlying, underlying mechanisms so

02:14.725 --> 02:16.645
that we can improve, different outcomes

02:16.745 --> 02:19.445
and particularly how we can improve, cognitive outcomes.

02:19.705 --> 02:23.445
The literature, really, is a little bit mixed.

02:23.785 --> 02:26.445
So in terms of the knowledge that hemoglobin is the thing

02:26.445 --> 02:30.165
that, is the problem in sickle cell, is well known,

02:30.235 --> 02:31.605
well established,

02:31.625 --> 02:34.005
and has really been sort of the heart of the research

02:34.005 --> 02:37.285
that we, we do, but how it might affect cognition.

02:37.285 --> 02:40.045
There's, some earlier studies that have looked at this,

02:40.545 --> 02:44.045
and that it's been a little bit mixed as to whether

02:44.045 --> 02:46.885
or not, hemoglobin might have this sort

02:46.885 --> 02:49.325
of more direct effect on cognition.

02:49.325 --> 02:51.605
Does there have to be, you know, we, we see changes

02:51.715 --> 02:52.765
that happen in the brain.

02:52.765 --> 02:55.485
Something called, oxygen, extraction fraction,

02:55.865 --> 02:57.005
blood flow.

02:57.025 --> 02:58.765
So these changes to the brain, but how much

02:58.785 --> 03:01.725
Is it that, hemoglobin changes these things?

03:01.745 --> 03:04.605
And then cognition, has been a little bit mixed.

03:04.945 --> 03:08.245
One of the reasons, we wanted to do this study was

03:08.245 --> 03:09.765
because what hadn't been done

03:09.765 --> 03:13.165
before was looking at hemoglobin longitudinally.

03:13.265 --> 03:15.565
So looking at over time, getting lots

03:15.565 --> 03:18.605
of different measurements from the children that we studied.

03:19.105 --> 03:22.525
Um, and so in some of my previous work, what we were able

03:22.525 --> 03:25.565
to show is that, for, children

03:25.565 --> 03:28.285
and young people who have sickle, oftentimes they are

03:28.795 --> 03:30.485
receiving blood transfusions.

03:30.485 --> 03:31.925
So they're getting blood transfusions

03:31.925 --> 03:35.525
because, they need to be able to,

03:36.075 --> 03:39.885
replace those sickle, blood cells,

03:39.955 --> 03:41.205
with healthy blood cells.

03:41.465 --> 03:43.805
And so in my previous research, we showed

03:43.835 --> 03:46.125
that the closer somebody is to that transfusion,

03:46.265 --> 03:49.725
the closer they've had to new hemoglobin coming in,

03:49.725 --> 03:51.885
the better they do on cognitive tasks.

03:51.985 --> 03:54.845
And then when we looked directly at hemoglobin, it seemed

03:54.885 --> 03:55.925
to show that that was there.

03:56.305 --> 03:58.685
So, we really wanted to be able to look at that,

03:58.705 --> 04:00.365
but look at lots of different measurements.

04:00.565 --> 04:01.685
'cause maybe it's because they're just

04:01.685 --> 04:02.765
looking at one measurement.

04:02.945 --> 04:04.285
We wanted to look at multiple.

04:04.545 --> 04:06.565
And so looking at multiple really is

04:06.585 --> 04:07.845
the, the key for this study.

04:07.865 --> 04:10.245
And then hopefully we can get a better idea of

04:10.245 --> 04:12.005
how people are doing over time.

04:12.545 --> 04:14.645
And what I had done in previous work,

04:14.665 --> 04:16.645
and there'd been some previous work in diabetes

04:16.865 --> 04:18.565
and, in my work in,

04:19.005 --> 04:21.525
a disorder called Phenyl Keel Noria, was to show

04:21.525 --> 04:25.925
that if you look at either blood in Phenyl, keel Noria,

04:26.465 --> 04:29.885
HB C one in diabetes, look at that over time.

04:30.515 --> 04:32.085
That is a better measurement.

04:32.185 --> 04:34.045
So is it, you know, looking at over time

04:34.065 --> 04:35.765
and is there variability over time?

04:35.765 --> 04:37.125
And that's what we wanted to do here.

04:37.475 --> 04:39.765
This is a longitudinal study, obviously be able

04:39.765 --> 04:41.085
to be able to do this over time.

04:41.465 --> 04:44.765
Uh, this study, was, there was a UK base

04:44.825 --> 04:48.085
and a US base, but we are primarily here in this study just

04:48.085 --> 04:49.565
look at, UK data.

04:50.305 --> 04:54.365
Um, and so we collected data from 2005 to 2014.

04:54.865 --> 04:58.085
Um, and we had looked at sort of every hemoglobin available

04:58.355 --> 05:01.085
that, the, children

05:01.085 --> 05:03.005
and young people had when they went into clinic.

05:03.065 --> 05:04.445
So when they go into clinic, they get their

05:04.615 --> 05:05.845
hemoglobin measured, right?

05:05.845 --> 05:07.845
We don't want it to going, too low

05:07.845 --> 05:10.285
because that's really indicative of anemia,

05:10.385 --> 05:13.205
and then we need to have a transfusion or intervention.

05:13.825 --> 05:16.685
Um, and then we also followed up again in 2017

05:16.865 --> 05:20.125
and 2019, we didn't report it here,

05:20.145 --> 05:22.685
but we, you know, we got multiple measures including MRI,

05:22.685 --> 05:25.645
but obviously we also got, cognitive data

05:25.865 --> 05:26.885
to be able to look at.

05:27.425 --> 05:30.285
Um, and in terms of our demographics, all of the children,

05:30.625 --> 05:33.725
were, identified as black British,

05:33.725 --> 05:35.885
about an even split of males and females.

05:35.945 --> 05:37.445
Uh, almost 50% of each.

05:37.865 --> 05:40.205
Um, we, almost all of them had,

05:40.645 --> 05:43.725
a genotype called the HBSS genotype,

05:43.725 --> 05:46.885
which is the most clinically severe form of sickle cell.

05:47.385 --> 05:49.925
Um, nearly half of the children had something called a

05:49.925 --> 05:53.525
silent infarction, which means that, which a lot

05:53.525 --> 05:55.965
of children with sickle cell, prior

05:56.025 --> 05:58.165
to our interventions used to have stroke,

05:58.505 --> 06:01.885
but still many children have something called an infarction.

06:01.885 --> 06:03.645
So there's still something there on the brain,

06:03.905 --> 06:07.165
but it hasn't, doesn't have outward neurologic signs,

06:07.225 --> 06:09.165
but still has an impact on the brain.

06:09.625 --> 06:13.485
And then about, a fifth of our children were taking,

06:13.645 --> 06:15.925
a drug called hydroxyurea, which is a drug

06:15.925 --> 06:19.205
that actually affects something called a fetal hemoglobin,

06:19.345 --> 06:21.285
so changes hemoglobin in some way.

06:21.745 --> 06:24.085
Um, and so we were able to look at,

06:24.085 --> 06:26.125
these different cognitive markers, particularly

06:26.125 --> 06:27.205
around processing speed

06:27.205 --> 06:29.245
and executive function, as I mentioned earlier.

06:29.625 --> 06:33.325
Um, and we also looked at the mean lifetime hemoglobin, so

06:33.325 --> 06:34.725
that hemoglobin over time.

06:35.145 --> 06:36.805
Uh, we looked at the median as well,

06:36.805 --> 06:39.005
just in case there were, you know, large,

06:39.005 --> 06:41.285
deviations from that mean, just to be able to get,

06:41.305 --> 06:42.605
a good measure.

06:42.705 --> 06:44.925
But they were reasonably similar actually, the mean

06:44.925 --> 06:47.205
and median, we looked at standard deviations

06:47.205 --> 06:48.325
that's looking at variability.

06:48.465 --> 06:50.405
So, so they're going up and down quite a lot.

06:50.425 --> 06:51.605
Or we've got like, you know,

06:51.895 --> 06:54.045
level staying, pretty similar.

06:54.625 --> 06:57.765
And then we also looked at, closest to data collection,

06:57.765 --> 06:59.605
which is what the other studies had normally done,

06:59.605 --> 07:03.085
just looked to see, is that, is that a,

07:03.635 --> 07:05.205
similar to a lifetime?

07:05.305 --> 07:07.445
Is that a good measure? And actually wasn't

07:07.445 --> 07:09.045
that different, but it was different.

07:09.225 --> 07:12.845
And so, generally looking at those, you know,

07:12.845 --> 07:15.965
those variables gave us more insight into be able to seeing

07:16.315 --> 07:19.925
what might be related to, cognition.

07:20.105 --> 07:23.805
And what we actually found was that,

07:24.675 --> 07:27.445
that processing speed measure, a measure of processing speed

07:27.825 --> 07:30.925
and, but not our measure of,

07:31.035 --> 07:35.085
working memory was significantly associated with hemoglobin

07:35.145 --> 07:39.805
and actually was associated with, the, mean,

07:39.865 --> 07:41.005
we didn't, we saw small,

07:41.025 --> 07:44.485
but non-significant correlations between,

07:44.595 --> 07:46.725
variability, in terms.

07:46.905 --> 07:50.165
And interestingly though, that medication that I mentioned,

07:50.505 --> 07:54.245
and was not related and neither was having that infarct.

07:54.465 --> 07:56.725
So it, in terms of the cognitive status,

07:56.865 --> 07:59.165
so it really was, seemed to be driven by

07:59.425 --> 08:01.605
how much oxygen does this child have to the brain?

08:02.025 --> 08:03.285
One of the things that,

08:03.345 --> 08:07.325
has come in the last few years is there has been really this

08:07.605 --> 08:10.565
proliferation of new drugs for sickle cell.

08:10.905 --> 08:14.045
Um, prior to, you know, really about this last five years,

08:14.105 --> 08:16.365
we really only had that one drug, the hydroxyurea

08:16.365 --> 08:18.285
that I mentioned, and chronic transfusion.

08:18.585 --> 08:20.125
So those were really our only tools.

08:20.425 --> 08:22.045
And so, more recently,

08:22.045 --> 08:25.205
and I think that which fits in with our findings is,

08:25.245 --> 08:26.805
there are, drugs now

08:26.805 --> 08:29.765
that are actually working on specifically,

08:29.765 --> 08:31.285
changes to hemoglobin.

08:31.465 --> 08:34.365
And so, there's a couple of drugs, one's called Altor,

08:34.505 --> 08:37.005
another is called acetor.

08:37.305 --> 08:39.805
Um, but both of those drugs actions work

08:39.865 --> 08:42.045
by increasing hemoglobin.

08:42.345 --> 08:46.485
And so, those types of, drugs are,

08:46.895 --> 08:49.685
their primary outcomes are to reduce, you know,

08:49.685 --> 08:53.285
this organ damage and secondary outcomes are to reduce pain.

08:53.505 --> 08:57.125
But what also seems to be happening, from our,

08:57.125 --> 08:59.845
studies, which suggest is that if we can re

09:00.105 --> 09:03.445
if we can make hemoglobin better, which is increasing it,

09:03.665 --> 09:06.525
we should also see these improvements in cognition.

09:07.025 --> 09:09.445
Um, you know, there are now curative options

09:09.445 --> 09:12.725
with sickle cell, but they're, they're very expensive.

09:12.985 --> 09:15.365
Um, so it was licensed here.

09:15.505 --> 09:17.925
CRISPR was licensed here in the UK very recently.

09:18.385 --> 09:21.565
Um, but it didn't pass NICE guidelines, which is

09:21.565 --> 09:23.405
what needs to be to get to the NHS.

09:23.405 --> 09:25.845
So currently costs sort of 1.5 million,

09:26.305 --> 09:27.365
to be able to do that.

09:27.415 --> 09:28.925
We're hoping to move towards that.

09:29.145 --> 09:32.925
Um, individuals, from my previous study in this study,

09:33.265 --> 09:36.005
it suggests the keeping, with chronic transfusions

09:36.005 --> 09:37.165
for those who are on them, because

09:37.475 --> 09:38.965
that really helps regulate.

09:39.225 --> 09:42.605
So hopefully now we've got sort of this, sort of toolkit

09:42.865 --> 09:45.405
for the, for our individuals living with sickle cell

09:45.545 --> 09:47.845
to think, okay, what, what might you need?

09:47.985 --> 09:50.405
Is it, is it one of these drugs, these medications

09:50.635 --> 09:52.405
that increase hemoglobin?

09:52.625 --> 09:55.645
Is it chronic transfusion or is it a curative option?

09:55.665 --> 09:57.765
But always thinking about this hemoglobin

09:57.765 --> 10:00.405
because it does seem to be having multiple effects,

10:00.505 --> 10:02.005
not only improving organ damage,

10:02.145 --> 10:04.165
but also improving what's happening in the brain,

10:04.165 --> 10:06.645
and particularly what's happening in cognitive functions.

10:07.005 --> 10:08.565
I think what we, would like

10:08.565 --> 10:10.645
to see is other longitudinal

10:11.085 --> 10:12.325
investigations of hemoglobin, right?

10:12.385 --> 10:14.685
So this is really one of the first to be able to do that.

10:14.685 --> 10:16.765
As I said, we're only looking at these static time points.

10:17.265 --> 10:20.845
And then with these investigations of these new drugs,

10:21.275 --> 10:22.965
look at having a cognition

10:23.025 --> 10:25.085
as an endpoint in a clinical trial.

10:25.385 --> 10:29.005
So currently, you know, oftentimes an endpoint is,

10:29.065 --> 10:31.325
you know, some form of this, clinical severity,

10:31.575 --> 10:32.685
which is very important.

10:32.865 --> 10:33.885
But patients

10:33.885 --> 10:37.005
and families tell us how important, you know, their kids

10:37.005 --> 10:38.885
and school is to them as well.

10:39.185 --> 10:42.525
And so we have written another paper that's shown that,

10:42.805 --> 10:45.925
provided cognitive tests that can be done, as part

10:45.965 --> 10:48.605
of clinical trials, provided some of the tools to be able

10:48.605 --> 10:50.245
to think how do you, how do you use them,

10:50.545 --> 10:52.365
how do you incorporate them into clinical trials?

10:52.425 --> 10:54.045
You know, obviously you'll still have your main

10:54.115 --> 10:55.165
primary outcomes.

10:55.255 --> 10:56.885
We're asking that they be incorporated

10:57.185 --> 10:59.245
as secondary outcomes in clinical trials as well.

"Understanding Sickle Cell Disease: Impact on Hemoglobin, Oxygen Delivery, and Cognitive Functioning"

00:00:00 - Sickle cell or sickle cell, disease or anemia, as it's often called, is actually the most common inherited disorder in the world and is actually the fastest growing inherited disorder here in the uk. and what it affects is the hemoglobin in our red blood cells. And so hemoglobin is what carries oxygen around the body. and in, sickle cell, that, process sort of breaks down. and, that process breaking down means the, red blood cells take on the shape of a sickle giving it its name, and it means that those cells are poor oxygen carriers. So they, you know, you've gotta get oxygen to all of our organs around the body, including the brain,
00:00:45 - really needs oxygen. and so those sickle cells don't carry oxygen very well. And unfortunately they're quite sticky and they get caught in the red blood cells, and, in our vessels and stop the healthy blood cells getting through. And so, one of the challenges that can face because of having lack of oxygen is to the brain, as I mentioned. And so not having enough oxygen to the brain, as you can imagine, can cause sort of this cascade of problems. But one of the things I'm particularly interested in is how that affects cognition. So the thinking abilities, what we need to be able to do at, at school to do well, for the chil, young children and young people.
00:01:26 - to manage our day-to-day lives. And so not having, enough hemoglobin that's going to the brain means that these cognitive challenges occur sort of across many different types of cognition, but particularly around, processing speed. So being able to take in information, understand what it is, and process it quickly. And something called executive functions, which are sort of these higher level, cognition challenges and thinking abilities. So being able to do multiple things at once or flex, be flexible from moving one to, from one thing to the other. And so this study was, because, myself and my colleagues have been interested in this area in
00:02:09 - and so what's the process, that's happening? What are the underlying, underlying mechanisms so that we can improve, different outcomes and particularly how we can improve, cognitive outcomes. The literature, really, is a little bit mixed. So in terms of the knowledge that hemoglobin is the thing that, is the problem in sickle cell, is well known, well established, and has really been sort of the heart of the research that we, we do, but how it might affect cognition. There's, some earlier studies that have looked at this, and that it's been a little bit mixed as to whether or not, hemoglobin might have this sort
00:02:49 - Does there have to be, you know, we, we see changes that happen in the brain. Something called, oxygen, extraction fraction, blood flow. So these changes to the brain, but how much Is it that, hemoglobin changes these things? And then cognition, has been a little bit mixed. One of the reasons, we wanted to do this study was because what hadn't been done before was looking at hemoglobin longitudinally. So looking at over time, getting lots of different measurements from the children that we studied. and so in some of my previous work, what we were able to show is that, for, children and young people who have sickle, oftentimes they are
00:03:30 - So they're getting blood transfusions because, they need to be able to, replace those sickle, blood cells, with healthy blood cells. And so in my previous research, we showed that the closer somebody is to that transfusion, the closer they've had to new hemoglobin coming in, the better they do on cognitive tasks. And then when we looked directly at hemoglobin, it seemed to show that that was there. So, we really wanted to be able to look at that, but look at lots of different measurements. 'cause maybe it's because they're just looking at one measurement. We wanted to look at multiple. And so looking at multiple really is the, the key for this study. And then hopefully we can get a better idea of

"Longitudinal Study on Hemoglobin Variability and Cognitive Function in Sickle Cell Disease: Insights and Findings"

00:04:12 - And what I had done in previous work, and there'd been some previous work in diabetes and, in my work in, a disorder called Phenyl Keel Noria, was to show that if you look at either blood in Phenyl, keel Noria, HB C one in diabetes, look at that over time. That is a better measurement. So is it, you know, looking at over time and is there variability over time? And that's what we wanted to do here. This is a longitudinal study, obviously be able to be able to do this over time. this study, was, there was a UK base and a US base, but we are primarily here in this study just look at, UK data.
00:04:54 - and we had looked at sort of every hemoglobin available that, the, children and young people had when they went into clinic. So when they go into clinic, they get their hemoglobin measured, right? We don't want it to going, too low because that's really indicative of anemia, and then we need to have a transfusion or intervention. and then we also followed up again in 2017 and 2019, we didn't report it here, but we, you know, we got multiple measures including MRI, but obviously we also got, cognitive data to be able to look at. and in terms of our demographics, all of the children,
00:05:33 - about an even split of males and females. almost 50% of each. we, almost all of them had, a genotype called the HBSS genotype, which is the most clinically severe form of sickle cell. nearly half of the children had something called a silent infarction, which means that, which a lot of children with sickle cell, prior to our interventions used to have stroke, but still many children have something called an infarction. So there's still something there on the brain, but it hasn't, doesn't have outward neurologic signs, but still has an impact on the brain. And then about, a fifth of our children were taking,
00:06:15 - that actually affects something called a fetal hemoglobin, so changes hemoglobin in some way. and so we were able to look at, these different cognitive markers, particularly around processing speed and executive function, as I mentioned earlier. and we also looked at the mean lifetime hemoglobin, so that hemoglobin over time. we looked at the median as well, just in case there were, you know, large, deviations from that mean, just to be able to get, a good measure. But they were reasonably similar actually, the mean and median, we looked at standard deviations that's looking at variability. So, so they're going up and down quite a lot. Or we've got like, you know, level staying, pretty similar.
00:06:57 - which is what the other studies had normally done, just looked to see, is that, is that a, similar to a lifetime? Is that a good measure? And actually wasn't that different, but it was different. And so, generally looking at those, you know, those variables gave us more insight into be able to seeing what might be related to, cognition. And what we actually found was that, that processing speed measure, a measure of processing speed and, but not our measure of, working memory was significantly associated with hemoglobin
00:07:39 - we didn't, we saw small, but non-significant correlations between, variability, in terms. And interestingly though, that medication that I mentioned, and was not related and neither was having that infarct. So it, in terms of the cognitive status, so it really was, seemed to be driven by how much oxygen does this child have to the brain? One of the things that, has come in the last few years is there has been really this proliferation of new drugs for sickle cell. prior to, you know, really about this last five years, we really only had that one drug, the hydroxyurea

Advancements in Sickle Cell Treatment: The Role of Hemoglobin-Targeting Drugs and Cognitive Outcomes**

00:08:18 - So those were really our only tools. And so, more recently, and I think that which fits in with our findings is, there are, drugs now that are actually working on specifically, changes to hemoglobin. And so, there's a couple of drugs, one's called Altor, another is called acetor. but both of those drugs actions work by increasing hemoglobin. And so, those types of, drugs are, their primary outcomes are to reduce, you know, this organ damage and secondary outcomes are to reduce pain. But what also seems to be happening, from our,
00:09:00 - if we can make hemoglobin better, which is increasing it, we should also see these improvements in cognition. you know, there are now curative options with sickle cell, but they're, they're very expensive. so it was licensed here. CRISPR was licensed here in the UK very recently. but it didn't pass NICE guidelines, which is what needs to be to get to the NHS. So currently costs sort of 1.5 million, to be able to do that. We're hoping to move towards that. individuals, from my previous study in this study, it suggests the keeping, with chronic transfusions for those who are on them, because
00:09:39 - So hopefully now we've got sort of this, sort of toolkit for the, for our individuals living with sickle cell to think, okay, what, what might you need? Is it, is it one of these drugs, these medications that increase hemoglobin? Is it chronic transfusion or is it a curative option? But always thinking about this hemoglobin because it does seem to be having multiple effects, not only improving organ damage, but also improving what's happening in the brain, and particularly what's happening in cognitive functions. I think what we, would like to see is other longitudinal investigations of hemoglobin, right? So this is really one of the first to be able to do that. As I said, we're only looking at these static time points. And then with these investigations of these new drugs,
00:10:57 - as an endpoint in a clinical trial. So currently, you know, oftentimes an endpoint is, you know, some form of this, clinical severity, which is very important. But patients and families tell us how important, you know, their kids and school is to them as well. And so we have written another paper that's shown that, provided cognitive tests that can be done, as part of clinical trials, provided some of the tools to be able to think how do you, how do you use them, how do you incorporate them into clinical trials? You know, obviously you'll still have your main primary outcomes. We're asking that they be incorporated as secondary outcomes in clinical trials as well.

Faculti AI can make mistakes

Research

Policy

Analysis